Janus Henderson Group
RUBY

Janus Henderson Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Janus Henderson Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-748,679
Closed -$7.11M – 1452
2019
Q4 		$7.11M Sell
748,679
-25,312
-3% -$245K ﹤0.01% 998
2019
Q3 		$6.08M Sell
773,991
-9,846
-1% -$115K ﹤0.01% 1030
2019
Q2 		$12.3M Sell
783,837
-44,621
-5% -$720K 0.01% 906
2019
Q1 		$15M Buy
+828,458
New +$12.7M 0.01% 835

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Janus Henderson Group's RUBY Position: Q1 2020 in Review

Janus Henderson Group sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2020, closing a stake of 748,679 shares — an estimated $7.11M sold.

Janus Henderson Group first reported a position in RUBY in Q1 2019 and held it in 4 quarters. The position peaked at $15M in Q1 2019. 76 funds tracked by Wall St. Rank hold RUBY as of Q1 2020.

  • Janus Henderson Group reported no remaining Rubius Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Janus Henderson Group sold 748,679 Rubius Therapeutics, Inc shares in Q1 2020, an estimated $7.11M.
  • Janus Henderson Group first reported a position in Rubius Therapeutics, Inc in Q1 2019 and held it in 4 quarters.
  • Janus Henderson Group's Rubius Therapeutics, Inc position peaked at $15M in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2020.

Based on Janus Henderson Group's 13F filing for Q1 2020, filed 14 May 2020.